Prof. Friedrich Breyer

Chair  of  Economic  and Social Policy,  University of Konstanz
(Germany),  Economics Department.

Member of the executive board and chairman, health economics committee
of the association of German-speaking economists (Verein für Socialpolitik);
member  of  the  advisory  board of the Federal  Ministry of  Economics and
Technology  (Germany);  Research  Professor  at  the  German  Institute of
Economic Research in Berlin;  author of a major  health economics textbook.


Prof. Martin J. Buxton

Professor  and  Director  of  the  Health Economics Research
Group (HERG)  at Brunel University,  London.

Over  20  years  experience in the methods and practice  of  economic  eval-
uation in health care; previously member of the Appraisal Committee of the
National  Institute for Clinical Excellence (NICE);  member of the Reference
Group  established by NICE to review the new Single Technology Appraisal
(STA) process.


Prof. Sören Holm

Professorial Fellow in Bioethics at Cardiff Law School, Cardiff
University, Wales.

Professor of  Medical Ethics  at the Universiy of Olso,  Norway;  editor-in-
chief  of  The Jornal of Medical Ethics;  member  of the  Danish Council  of
Ethics from 1994 to 1999;  currently  President-Elect of the European So-
ciety for the Philosophy of Medicine and Health Care.


Wolfgang Kaesbach

Board  member of the  German Federal  Association of Com-
pany  Sickfunds  (Bundesverband  der  Betriebskrankenkas-
sen, BKK).

Member of the Medicine Evaluation Committee (MEDEV), European Social
Health  Insurance Forum;  head  of department  of pharmaceutical and me-
dical  products  at  BKK,  the  lead  organization  of  the  German  Statutory
Health Insurance on pharmaceutical pricing and reimbursement.


Prof. Panos Kanavos

Lecturer in  International Health Policy  and Merck Fellow in
Pharmaceutical  Economics at the  London School of Econo-
mics (LSE).

Advisor to the World Bank, the World Health Organization and the Organi-
sation for Economic Cooperation and Development  (OECD),  the American
Association  for Retired Persons  and Ministries  of Health in over 14 transi-
tion and developing countries.


Dr. Peter Kolominsky-Rabas

Head of the  Department for Health  Economics  at  the Ger-
man   Institute   for  Quality  and  Efficiency  in  Health  Care
(IQWiG),  Cologne  (Germany).

Founder and  previous Scientific Director of the Interdisciplinary Center for
Public  Health Studies at the University of Erlangen  (Germany);  Chairman
of the Health Economics and Outcomes Research Committee of the German
Stroke Association (DSG);  Managing Board Member of the Bavarian Public
Health Network.


Prof. Andreas Laupacis

Professor,  Department of Health Policy,  Management and
Evaluation, at the University of Toronto, and Director, Li Ka
Shing Knowledge Institute, Toronto.

Over  20  years  experience in  cost-effectiveness  and quality-of-life  mea-
surement studies; member of Health Canada’s Advisory Board; previously
Chief Executive Officer  of the  Institute  for  Clinical  Evaluative  Sciences;
formerly  senior  scientist  of  the  Canadian Institutes of  Health Research;
first chair of the Canadian Expert Drug Advisory Committee.


Christine Lavery

Chief Executive, Society for  Mucopolysaccharide and Rela-
ted Diseases (MPS), Amersham/Buckinghamshire, England
(since 1993).

Prior to that,  between 1984 and 1993 employed as  National Development
Officer at Contact a Family,  a UK charity;  awarded Member of the British
Empire by the Queen in 2002; recipient of A Life Time Award from the In-
ternational MPS Community for her services to metabolic diseases.


Dr. Ulf Persson

Research Director at The Swedish Institute for Health Eco-
nomics (IHE), Lund (Sweden).

Over 20 years research experience in the development and application of
economic evaluation methods in health care,  with particular regard to the
introduction and utilization of medical technologies.


Prof. Jeff Richardson

Professor  in the  Faculty of Business  and  Economics at
Monash  University   ( Melbourne  /  Clayton,  Victoria );
Foundation Director of the Centre for Health Economics (CHE).

President of the  Australian  Health  Economists’ Group  from  1984  to
1991; member of the Pharmaceutical Remuneraton Tribunal in Austra-
lia;  member of the editorial boards of five leading health economic jour-
nals.


Prof. Michael Schlander1

Founding Chairman  of the Instiute  for Innovation  &  Valua-
tion in  Health  Care  (  );  Professor  of  Health  Care
Management at the  University of Applied Economic Sciences
Ludwigshafen (Germany);  visiting scientist at the Mannheim
Institute of Public Health (University of Heidelberg).

Research  interests include the use of economic methods to  evaluate health
technologies as well as pharmaceutical markets and their regulation; mental
health  policy and economics;  over  15  years  experience in senior manage-
ment roles in the international pharmaceutical industry.


Prof. Rosalie Viney

University of Technology Sydney, Centre for Health Econo-
mics Research & Evaluation.

Ph.D.  (Economics,  Syd),  M.Ec. (Tas),  B.Ec. (Hons.);  Deputy  Director  of
CHERE, member of the Australian Pharmaceutical Benefits Advisory Com-
mittee (PBAC)'s Economics Subcommittee; research focus on the valuation
of  health  outcomes  (discrete  choice  experiments,  Quality-Adjusted Life-
Years).


Koen Torfs

Vice President, Health Economics & Public Affairs, Janssen-
Cilag GmbH (Neuss, Germany).

Over 20 years experience in the economic evaluation of health care inter-
ventions.


1  Scientific Program Director